Get the Stockscreener App
157.94
1.10%
1.515
Neurocrine Biosciences Inc stock is traded at $157.94, with a volume of 51,171.
It is up +1.10% in the last 24 hours and down -0.17% over the past month.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
See More
Previous Close:
$156.42
Open:
$156.62
24h Volume:
51,171
Relative Volume:
0.04
Market Cap:
$15.88B
Revenue:
$3.10B
Net Income/Loss:
$668.60M
P/E Ratio:
24.28
EPS:
6.5044
Net Cash Flow:
$831.30M
1W Performance:
-1.69%
1M Performance:
-0.17%
6M Performance:
+11.61%
1Y Performance:
+26.64%
1-Day Range:
$155.66
$158.64
1-Week Range:
$155.30
$164.04
52-Week Range:
$122.14
$169.57
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
157.96 | 16.04B | 3.10B | 668.60M | 831.30M | 6.5044 |
TAK
Takeda Pharmaceutical Co Adr
|
15.48 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.035 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.76 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.33 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
554.22 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-21-25 | Initiated | Citigroup | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High-Growth Momentum Breakout Candidate - ChartMill
Neurocrine presents case study on Crenessity for rare CAH subtype By Investing.com - Investing.com Australia
Neurocrine presents long-term data on Prader-Willi drug By Investing.com - Investing.com Australia
Neurocrine presents case study on Crenessity for rare CAH subtype - Investing.com
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period - PR Newswire
Neurocrine Biosciences (NBIX) Presents First Retrospective Case Series of CRENESSITY - StreetInsider
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026 - PR Newswire
Is Neurocrine Biosciences, Inc. (NBIX) A Good Stock To Buy Now? - Insider Monkey
Neurocrine presents 2-year Crenessity data at ENDO 2026 By Investing.com - Investing.com South Africa
Neurocrine (NBIX) Reports Positive Phase 3 Data on Crenessity - GuruFocus
Neurocrine reports positive 2-year pediatric CAH data - grafa.com
Two-year data bolster Neurocrine’s Crenessity case in pediatric CAH - The Pharma Letter
Neurocrine presents 2-year Crenessity data at ENDO 2026 - Investing.com UK
Neurocrine Biosciences Presents New Two-Year CRENESSITY Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults With Classic Congenital Adrenal Hyperplasia - marketscreener.com
Neurocrine presents two-year pediatric data for Crenessity - Investing.com
Neurocrine presents two-year CRENESSITY data showing growth improvements - StreetInsider
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026 - PR Newswire
Neurocrine shows two-year CRENESSITY data at ENDO 2026 medical meeting - StreetInsider
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improvements in Cardiometabolic Outcomes in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2026 - PR Newswire
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Investor Outlook Highlights 20.73% Potential Upside - DirectorsTalk Interviews
How New INGREZZA TD Data in Underserved Patients Could Shape Neurocrine Biosciences’ (NBIX) Investment Story - simplywall.st
Marquis Who's Who Honors Noah Post for Expertise in Pharmaceuticals - 24-7 Press Release Newswire
Assessing Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Momentum - simplywall.st
Neurocrine Biosciences (NBIX) beats Q1 earnings and revenue estimates - MSN
INGREZZA Data In Complex Patients Adds Support For Neurocrine Valuation Story - simplywall.st
Tom Lee's Small-Cap Granny Shots ETF Reloads: First Solar, Zoom Among 10 New Buys - Benzinga
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Growth Stock Pick from the Little Book Strategy - ChartMill
Neurocrine Biosciences(NBIX.US) Director Sells US$4.13 Million in Common Stock - Moomoo
Neurocrine Biosciences director Stephen A. Sherwin sells $4.13m stock - Investing.com UK
Neurocrine Biosciences director Stephen A. Sherwin sells $4.13m stock By Investing.com - Investing.com Canada
Neurocrine (NBIX) director exercises 25K options and sells 25K shares under 10b5-1 plan - Stock Titan
[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity - Stock Titan
Transcript : Neurocrine Biosciences, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 09 - marketscreener.com
Neurocrine Biosciences (NBIX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Cerebral Palsy Market Positioned for Significant Commercial Growth by 2036 – DelveInsight | Neurocrine Biosciences, Teva Pharma, Bundang CHA Hospital, Jazz Pharma - Barchart.com
Neurocrine presents tardive dyskinesia treatment data at conference - StreetInsider
Neurocrine Biosciences director sells $210,071 in stock By Investing.com - Investing.com South Africa
Neurocrine Biosciences director sells $210,071 in stock - Investing.com
Neurocrine (NBIX) director sells 1,250 shares under Rule 10b5-1 plan - Stock Titan
Drug for uncontrollable movements eased symptoms in 94% of patients over 48 weeks - Stock Titan
Neurocrine reports positive INGREZZA data for TD in patients with IDD - grafa.com
Neurocrine presents data on tardive dyskinesia treatment - Investing.com
Neurocrine presents data on tardive dyskinesia treatment By Investing.com - Investing.com Australia
Doctors report TD reductions, better speech and socializing with INGREZZA - Stock Titan
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Nears Technical Breakout with Near-Perfect Score - ChartMill
Neurocrine publishes dosing guidelines for CAH treatment drug - Investing.com
Neurocrine Biosciences Inc. (NBIX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
[144] NEUROCRINE BIOSCIENCES INC SEC Filing - Stock Titan
Behavioral Patterns of NBIX and Institutional Flows - Stock Traders Daily
Does Neurocrine Biosciences’ (NBIX) Rare Disease Push Quietly Rewire Its Endocrine Risk-Reward Profile? - simplywall.st
Oppenheimer raises Neurocrine Bio stock price target on strong results - Investing.com
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neurocrine Biosciences Inc Stock (NBIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SHERWIN STEPHEN A | Director |
Jun 05 '26 |
Sale |
165.32 |
25,000 |
4,132,969 |
15,860 |
| Norwalk Leslie V | Director |
Jun 04 '26 |
Sale |
168.06 |
1,250 |
210,072 |
2,838 |
0.19%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):